User profiles for Guido Moll

Guido Moll

Charité Universitätsmedizin Berlin
Verified email at charite.de
Cited by 4605

RETRACTED: tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study

…, B Leidner, T Lilja, J Liska, T Luedde, V Lundin, G Moll… - The lancet, 2011 - thelancet.com
Background Tracheal tumours can be surgically resected but most are an inoperable size at
the time of diagnosis; therefore, new therapeutic options are needed. We report the clinical …

Impact of cryopreservation and freeze-thawing on therapeutic properties of mesenchymal stromal/stem cells and other common cellular therapeutics

…, A Lipat, C Turner-Lyles, J Nguyen, G Moll… - Current stem cell …, 2022 - Springer
Purpose of Review Cryopreservation and its associated freezing and thawing procedures–short
“freeze-thawing”–are among the final steps in economically viable manufacturing and …

Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?

G Moll, JJ Alm, LC Davies, L von Bahr, N Heldring… - Stem …, 2014 - academic.oup.com
We have recently reported that therapeutic mesenchymal stromal cells (MSCs) have low
engraftment and trigger the instant blood mediated inflammatory reaction (IBMIR) after systemic …

Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements

J Doorn, G Moll, K Le Blanc… - … Engineering Part B …, 2012 - liebertpub.com
Among the various types of cell-to-cell signaling, paracrine signaling comprises those signals
that are transmitted over short distances between different cell types. In the human body, …

Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial

A Roemhild, NM Otto, G Moll, M Abou-El-Enein… - bmj, 2020 - bmj.com
Objective To assess whether reshaping of the immune balance by infusion of autologous
natural regulatory T cells (nTregs) in patients after kidney transplantation is safe, feasible, and …

Are therapeutic human mesenchymal stromal cells compatible with human blood?

G Moll, I Rasmusson-Duprez, L von Bahr… - Stem …, 2012 - academic.oup.com
Multipotent mesenchymal stromal cells (MSCs) are tested in numerous clinical trials. Questions
have been raised concerning fate and function of these therapeutic cells after systemic …

Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines

G Moll, JA Ankrum, J Kamhieh-Milz, K Bieback… - Trends in molecular …, 2019 - cell.com
Intravascular infusion is the most popular route for therapeutic multipotent mesenchymal
stromal/stem cell (MSC) delivery in hundreds of clinical trials. Meta-analysis has demonstrated …

Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses

G Moll, R Jitschin, L von Bahr, I Rasmusson-Duprez… - PloS one, 2011 - journals.plos.org
Infusion of human third-party mesenchymal stromal cells (MSCs) appears to be a promising
therapy for acute graft-versus-host disease (aGvHD). To date, little is known about how …

Cryopreserved or fresh mesenchymal stromal cells: only a matter of taste or key to unleash the full clinical potential of MSC therapy?

G Moll, S Geißler, R Catar, L Ignatowicz… - … and cryopreservation of …, 2016 - Springer
Mesenchymal stromal cells (MSCs) harbor great therapeutic potential for numerous
diseases. From early clinical trials, success and failure analysis, bench-to-bedside and back-to-…

Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua

G Moll, L Ignatowicz, R Catar, C Luecht… - Stem cells and …, 2015 - liebertpub.com
While therapeutic mesenchymal stromal/stem cells (MSCs) have usually been obtained from
bone marrow, perinatal tissues have emerged as promising new sources of cells for stromal …